Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
Date:2/13/2008

od screening

manufacturing facility located in Rancho Bernardo, California. The

Company had leased the 94,000-square-feet facility since late 1997.

The transaction is expected to have an immaterial effect on

Gen-Probe's income statement in 2008, but is expected to be accretive

to earnings over the long term, based on rent increases that would

have been associated with renewing the Company's lease. "The purchase

of our state-of-the-art blood screening manufacturing facility on

attractive financial terms reflects our long-term commitment to

providing innovative nucleic acid tests that safeguard the world's

supply of donated blood," said Mr. Hull.

Webcast Conference Call

A live webcast of Gen-Probe's fourth quarter 2007 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is (800) 308-7858 for domestic callers and (402) 220-3841 for international callers.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.

Trademarks

APTIMA, APTIMA COMBO 2, PACE and TIGRIS are trademarks of Gen-Probe. ULTRIO and P
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Carl Hull Named President and Chief Operating Officer of Gen-Probe
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
5. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with ... used for drug discovery to commercial manufacturing, announced today ... Next-Generation Sequencing (NGS) data packages. The NGS analysis ... ensuring the integrity of the gene, validation of the ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... ATLANTA, April 4, 2011 CryoLife, Inc. (NYSE: ... processing company, announced today that it has filed ... (FDA) to begin clinical trials for the purpose of obtaining ... control bleeding during surgical procedures or following traumatic injuries. ...
... ORLEANS, April 4, 2011 Orexigen ® ... additional data that showed that overweight and obese ... SR) maintained normal 24-hour circadian patterns over one ... ambulatory blood pressure monitoring (ABPM) sub-study of the ...
... (NASDAQ: OMER ), a biopharmaceutical company committed ... bleeding and disorders of the central nervous system, today ... executive officer, is scheduled to present at the 10th ... City this week.  The presentation is scheduled for Tuesday, ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 2Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 3Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 4
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... today at its 2005 international symposium on Computational ... Folding Project launched on IBM's World Community Grid ... structures. , "This project showcases the enormous power ... at the Institute for Systems Biology. "Through a ...
... body's infection-fighting cells might also contribute to fatty buildups ... Southwestern Medical Center researchers have found. , The molecule, ... death in macrophages, which circulate in the bloodstream and ... The AIM-protected macrophages go on to encourage buildup of ...
... life detection system developed by Carnegie Mellon University scientists ... according to results being presented at the 36th Lunar ... marks the first time a rover-based automated technology has ... which serves as a test bed for technology that ...
Cached Biology News:Institute for Systems Biology Symposium Addresses Need for Better Computational Tools 2Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries 2Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 2Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 3Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 4
Anti-rat Dipeptidyl Peptidase IV (DPP IV), CD26, Clone 5E8, Monoclonal Antibody...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
... H3 (Lys 4) Immunogen: ... ...RT[ Ac K]Q... in which [ Ac ... human histone H3 Accession ... Weight: Mr ~17kDa ...
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Biology Products: